← Back to Clinical Trials
Recruiting NCT06185686

NCT06185686 Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06185686
Status Recruiting
Phase
Sponsor Washington University School of Medicine
Condition Brain Tumor, Primary
Study Type OBSERVATIONAL
Enrollment 16 participants
Start Date 2024-07-10
Primary Completion 2027-07-31

Eligibility & Interventions

Sex All sexes
Min Age 8 Years
Max Age 21 Years
Study Type OBSERVATIONAL
Interventions
Cognitive testingResting State MRI/Precision functional mapping

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 16 participants in total. It began in 2024-07-10 with a primary completion date of 2027-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

With modern therapy, the survival rate for pediatric brain tumor patients has significantly improved, with over 70% of patients surviving their disease. However, this progress often comes at the cost of substantial morbidity, with cognitive deficits being the primary obstacle to independent living. Robust predictors of cognitive decline and a comprehensive understanding of the underlying mechanisms of cognitive injury remain elusive. This study will prospectively investigate alterations in brain resting state networks following radiation therapy using functional imaging. The hypothesis is that radiation therapy leads to dose-dependent alterations in functional connectivity in the networks associated with higher level cognition, ultimately leading to cognitive decline.

Eligibility Criteria

Inclusion Criteria: * Between 8 and 21 years of age, inclusive * Newly diagnosed primary brain tumor of any location and any histology that will be treated with proton radiation therapy * Life expectancy of at least one year * Able to understand and willing to consent or assent to the research proposed (or that of a legally authorized representative, if applicable), along with consent of legal guardian(s) if applicable Exclusion Criteria: * Presence of visual impairment to an extent that the patient is unable to complete the computer testing * Contraindication to MRI scan (i.e. due to cardiac pacemaker) * Presence of programmable shunt or dental braces * Requires sedation for MRI scans

Contact & Investigator

Central Contact

Stephanie Perkins, M.D.

✉ sperkins@wustl.edu

📞 314-747-4405

Principal Investigator

Stephanie Perkins, M.D.

PRINCIPAL INVESTIGATOR

Washington University School of Medicine

Frequently Asked Questions

Who can join the NCT06185686 clinical trial?

This trial is open to participants of all sexes, aged 8 Years or older, up to 21 Years, studying Brain Tumor, Primary. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06185686 currently recruiting?

Yes, NCT06185686 is actively recruiting participants. Contact the research team at sperkins@wustl.edu for enrollment information.

Where is the NCT06185686 trial being conducted?

This trial is being conducted at St Louis, United States.

Who is sponsoring the NCT06185686 clinical trial?

NCT06185686 is sponsored by Washington University School of Medicine. The principal investigator is Stephanie Perkins, M.D. at Washington University School of Medicine. The trial plans to enroll 16 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology